Cargando…

Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD

INTRODUCTION: Mounting evidence indicates that a disturbed Wnt–β-catenin signaling may be involved in the pathogenesis of chronic kidney disease-mineral and bone and mineral disorder (CKD-MBD). Data on the impact of CKD on circulating levels of the Wnt antagonists sclerostin and Dickkopf related pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Behets, Geert J., Viaene, Liesbeth, Meijers, Björn, Blocki, Frank, Brandenburg, Vincent M., Verhulst, Anja, D’Haese, Patrick C., Evenepoel, Pieter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5426702/ https://www.ncbi.nlm.nih.gov/pubmed/28493902 http://dx.doi.org/10.1371/journal.pone.0176411

Ejemplares similares

Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease
por: De Maré, Annelies, et al.
Publicado: (2019)

Osteocytic Sclerostin Expression as an Indicator of Altered Bone Turnover
por: Huybrechts, Yentl, et al.
Publicado: (2023)

The Role of Sclerostin in Bone and Ectopic Calcification
por: De Maré, Annelies, et al.
Publicado: (2020)

Sclerostin Protects Against Vascular Calcification Development in Mice
por: De Maré, Annelies, et al.
Publicado: (2022)

Sclerostin as Regulatory Molecule in Vascular Media Calcification and the Bone–Vascular Axis
por: De Maré, Annelies, et al.
Publicado: (2019)

Prevention and Treatment of CKD-MBD
por: Cozzolino, Mario
Publicado: (2013)

Towards a better understanding of arterial calcification disease progression in CKD: investigation of early pathological alterations
por: Van den Bergh, Geoffrey, et al.
Publicado: (2022)

CKD-MBD after kidney transplantation
por: Wesseling-Perry, Katherine, et al.
Publicado: (2011)

A Japanese approach for CKD-MBD
por: Yokoyama, Keitaro, et al.
Publicado: (2013)

The Role of Vitamin K in CKD-MBD
por: Fusaro, Maria, et al.
Publicado: (2022)

CKD-MBD diagnosis: biochemical abnormalities
por: Lucca, Leandro Junior, et al.
Publicado: (2021)

Renoprotective effects of sucroferric oxyhydroxide in a rat model of chronic renal failure
por: Neven, Ellen, et al.
Publicado: (2020)

Management of fracture risk in CKD—traditional and novel approaches
por: Haarhaus, Mathias, et al.
Publicado: (2022)

Clinical significance of parathyroid intervention on CKD-MBD management
por: Ogata, Hiroaki, et al.
Publicado: (2008)

COMBINING SCLEROSTIN AND DKK1 INHIBITORS TO IMPROVE BONE PROPERTIES IN THE AGED SKELETON
por: Choi, Roy, et al.
Publicado: (2022)

Heritability and Clinical Determinants of Serum Indoxyl Sulfate and p-Cresyl Sulfate, Candidate Biomarkers of the Human Microbiome Enterotype
por: Viaene, Liesbeth, et al.
Publicado: (2014)

Cardiovascular disease relates to intestinal uptake of p-cresol in patients with chronic kidney disease
por: Poesen, Ruben, et al.
Publicado: (2014)

No Evidence for Statin-induced Proteinuria in Healthy Volunteers as Assessed by Proteomic Analysis
por: Verhulst, Anja, et al.
Publicado: (2011)

FGF-23 and sclerostin in serum and bone of CKD patients
por: Lima, Florence, et al.
Publicado: (2023)

Gaps between Global Guidelines and Local Practices in CKD-MBD
por: Kim, Gheun-Ho
Publicado: (2014)

Which Vitamin D in CKD-MBD? The Time of Burning Questions
por: Galassi, Andrea, et al.
Publicado: (2013)

CKD-MBD KDIGO guidelines: how difficult is reaching the ‘target’?
por: Cozzolino, Mario
Publicado: (2018)

CKD-MBD in Brazil: the gap between reality and the recommended guidelines
por: Custódio, Melani Ribeiro
Publicado: (2018)

Diagnosis of bone abnormalities in CKD-MBD (Imaging and bone biopsy)
por: Bucharles, Sérgio Gardano Elias, et al.
Publicado: (2021)

Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients
por: Sprangers, Ben, et al.
Publicado: (2020)

Metformin and Canagliflozin Are Equally Renoprotective in Diabetic Kidney Disease but Have No Synergistic Effect
por: Corremans, Raphaëlle, et al.
Publicado: (2023)

Molecular and Cellular Mechanisms that Induce Arterial Calcification by Indoxyl Sulfate and P-Cresyl Sulfate
por: Opdebeeck, Britt, et al.
Publicado: (2020)

Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone fragility associated with Turner syndrome
por: Chiarito, M., et al.
Publicado: (2022)

Serum sclerostin in vascular calcification in CKD: a meta-analysis
por: Lin, Yan, et al.
Publicado: (2023)

Role of Chronic Kidney Disease (CKD)–Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD
por: Yamada, Shunsuke, et al.
Publicado: (2023)

Association between CKD-MBD and mortality in older patients with advanced CKD—results from the EQUAL study
por: Magagnoli, Lorenza, et al.
Publicado: (2023)

Sclerostin─A Debutant on the Autosomal Dominant Polycystic Kidney Disease Scene?
por: Jankowska, Magdalena, et al.
Publicado: (2017)

Should We Consider the Cardiovascular System While Evaluating CKD-MBD?
por: Rroji, Merita, et al.
Publicado: (2020)

Testing Patterns for CKD-MBD Abnormalities in a Sample US Population
por: Wetmore, James B., et al.
Publicado: (2021)

Can we reverse arterial stiffness by intervening on CKD-MBD biomarkers?
por: Vervloet, Marc G
Publicado: (2023)

Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate
por: Persy, Veerle P, et al.
Publicado: (2009)

Environmental toxin-induced acute kidney injury
por: Vervaet, Benjamin A, et al.
Publicado: (2017)

Sclerostin and DKK1 circulating levels associate with low bone turnover in patients with chronic kidney disease Stages 3 and 4
por: Neto, Ricardo, et al.
Publicado: (2021)

A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair
por: Florio, Monica, et al.
Publicado: (2016)

Co-expression of DKK-1 and Sclerostin in Subchondral Bone of the Proximal Femoral Heads from Osteoarthritic Hips
por: Zarei, Allahdad, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n7rc06cgb2gnhpt01g407gstlu